25 results about "Calcium channel blocker" patented technology

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker, wherein the dose of each component is below the lowest dose approved for the treatment of hypertension for the component.

This article provides a pharmaceutical composition for the treatment of hypertension, comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

The present invention is related to methods of treating cardiac arrhythmia, angina, or a migraine in a patient in need thereof, with a therapeutically effective amount of a compound having a structure according to the formula:the method comprising nasally administering to the patient (i) a first dose, and (ii) a second dose of an aqueous composition comprising a pharmaceutically acceptable acetate or methanesulfonate salt of compound I, or a racemate or enantiomer thereof, wherein the acetate or methanesulfonate salt of compound I, or the racemate or enantiomer thereof, is dissolved in the aqueous composition at a concentration of 350 mg / mL±50 mg / mL, and wherein the second dose of the compound is administered between 5 minutes and 25 minutes after the first dose.

The present invention concerns the use of an L-type calcium channel (LTCC) blocker in combination with a BRAF inhibitor (BRAFi) and / or a MEK inhibitor (MEKi) for the treatment of melanoma in a patient.

Provided herein are methods and compositions for the treatment of hearing impairment by administering a combination of two or more calcium channel blockers.

A pharmaceutical composition comprising azilsartan medoxomil potassium and a calcium channel blocker, a method for preparing same, and use thereof are provided. Azilsartan medoxomil potassium and the calcium channel blocker are formulated into a compound formulation, thus improving the blood pressure lowering efficacy, improving safety and tolerability, and reducing adverse effects. Azilsartan medoxomil potassium can ameliorate peripheral edema caused by amlodipine by means of expanding peripheral venous vessels, while amlodipine can ameliorate adverse effects such as vasogenic edema, dry cough, and the like caused by azilsartan medoxomil potassium.

The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.

The invention discloses application of an L-type calcium channel blocker as a ferroptosis inhibitor in preparation of drugs, and belongs to the technical field of biological medicines. In order to solve the problem that an effective acute pancreatitis and organ injury treatment means is lacked in the prior art, the invention provides application of an L-type calcium channel blocker as a ferroptosis inhibitor in preparation of a medicine for preventing / treating acute pancreatitis and organ injury, and the L-type calcium channel blocker is Benidipine, Xinidipine or Manidipine; proved by detection such as western blot and the like, the L-type calcium channel blocker can inhibit activation of ferroptosis key protein and generation of intracellular lipid active oxygen, is high in safety and provides a new means for disease treatment.

A pharmaceutical composition comprising a diuretic and at least one additional active ingredient selected from the group consisting of ACE inhibitors, sartans, calcium channel blockers, alpha blockers, and beta blockers, wherein the diuretic is in a first pharmaceutical form that increases its dissolving rate. The invention also relates to the above composition for use in the treatment of a condition selected from heart failure, arterial hypertension, myocardial fibrosis, and cardiac hypertrophy.

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Provided herein are methods and compositions for the treatment of hearing disorders by administration of a combination of two or more calcium channel blockers.

To provide compositions for the treatment of hypertension. [Solution] This specification provides pharmaceutical compositions useful for the treatment of hypertension, comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker. These compositions are administered at 40% to 80% of the minimum hypertension therapeutic dose (LHTD) for each agent. This application also relates to compositions comprising telmisartan, a thiazide-like diuretic, and a calcium channel blocker, administered at 80% to 150% of the LHTD for each agent.

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

The invention discloses an external eye protection liquid for relieving asthenopia and a preparation method thereof.The eye protection liquid comprises a plant-derived calcium channel blocker, a divalent metal ion source, a temperature-sensitive gel matrix and a deep eutectic solvent system, has unique reversible phase change characteristics, is flowing sol during low-temperature storage, and can be used for relieving asthenopia. And after contacting the ocular surface, in-situ phase change is rapidly generated to form semi-solid gel. In the preparation process, a choline chloride-propylene glycol deep eutectic solvent is adopted to carry out low-temperature in-situ extraction on plant raw materials, an extracting solution is directly used as a functional component to be reserved in the preparation, and a cold-soluble compounding process of a poloxamer matrix is matched, so that the damage of high temperature to active components in the whole process is avoided. The problems that a traditional aqueous solution is short in retention time on the ocular surface and low in bioavailability, and the drug effect is damaged by a high-temperature process are solved, and deep eyestrain is effectively relieved through physical and physiological dual mechanisms.

The present invention provides a pharmaceutical composition comprising azilsartan medoxomil potassium and a calcium channel blocker, a method for preparing same, and use thereof. Azilsartan medoxomil potassium and the calcium channel blocker are formulated into a compound formulation, thus improving the blood pressure lowering efficacy, improving safety and tolerability, and reducing adverse effects. Azilsartan medoxomil potassium can ameliorate peripheral edema caused by amlodipine by means of expanding peripheral venous vessels, while amlodipine can ameliorate adverse effects such as vasogenic edema, dry cough, and the like caused by azilsartan medoxomil potassium. Compared with the monotherapies, the combination has the advantages of (1) reducing the number of doses and thus improving patient compliance; (2) improving the compliance in seniors or those with dysphagia; (3) preventing frequent fluctuation in plasma drug concentration, maintaining a stable plasma concentration, maintaining the long-term stability of blood pressure in patients with hypertension, and reducing the adverse effects of the drugs; and (4) preventing arbitrary treatment interruption, and thus preventing disease recurrence and the development of malignant complications.

The present disclosure relates to methods and pharmaceutical compositions of angiotensin converting enzyme inhibitor and calcium channel blocker, particularly stable oral liquid compositions including angiotensin converting enzyme inhibitor, calcium channel blocker and one or more pharmaceutically acceptable excipients for the treatment of hypertension, coronary artery disease, heart failure, acute myocardial infarction and other related cardiovascular diseases.

The present invention provides compounds of formula (I) which act as a calcium channel blocker, for use in the prevention and / or treatment of diseases associated with dysfunction of the calcium channels and / or imbalance in intracellular calcium homeostasis, such as hypertension, Raynaud's disease, migraine, migraine prophylaxis, viral infections, angina, arrhythmias, subarachnoid hemorrhage, hypertrophic cardiomyopathy, esophageal spasm, and pulmonary hypertension, as well as a composition and a pharmaceutical composition comprising said compounds.

The present disclosure relates to methods and pharmaceutical compositions of angiotensin converting enzyme inhibitor and calcium channel blocker, particularly stable oral liquid compositions including angiotensin converting enzyme inhibitor, calcium channel blocker and one or more pharmaceutically acceptable excipients for the treatment of hypertension, coronary artery disease, heart failure, acute myocardial infarction and other related cardiovascular diseases.